268 related articles for article (PubMed ID: 35971893)
1. Is psychedelic use associated with cancer?: Interrogating a half-century-old claim using contemporary population-level data.
Barnett BS; Ziegler K; Doblin R; Carlo AD
J Psychopharmacol; 2022 Oct; 36(10):1118-1128. PubMed ID: 35971893
[TBL] [Abstract][Full Text] [Related]
2. Psychedelic Psychiatry and the Consult-Liaison Psychiatrist: A Primer.
Barnett BS; Greer GR
J Acad Consult Liaison Psychiatry; 2021; 62(4):460-471. PubMed ID: 34210406
[TBL] [Abstract][Full Text] [Related]
3. Associations between lifetime classic psychedelic use and markers of physical health.
Simonsson O; Sexton JD; Hendricks PS
J Psychopharmacol; 2021 Apr; 35(4):447-452. PubMed ID: 33719688
[TBL] [Abstract][Full Text] [Related]
4. Population Survey Data Informing the Therapeutic Potential of Classic and Novel Phenethylamine, Tryptamine, and Lysergamide Psychedelics.
Sexton JD; Nichols CD; Hendricks PS
Front Psychiatry; 2019; 10():896. PubMed ID: 32116806
[TBL] [Abstract][Full Text] [Related]
5. Assessing the risk-benefit profile of classical psychedelics: a clinical review of second-wave psychedelic research.
Bender D; Hellerstein DJ
Psychopharmacology (Berl); 2022 Jun; 239(6):1907-1932. PubMed ID: 35022823
[TBL] [Abstract][Full Text] [Related]
6. The psychedelic call: analysis of Australian Poisons Information Centre calls associated with classic psychedelics.
Wilkes R; Roberts DM; Liknaitzky P; Brett J
Clin Toxicol (Phila); 2024 Apr; 62(4):242-247. PubMed ID: 38753585
[TBL] [Abstract][Full Text] [Related]
7. Psychedelics: Alternative and Potential Therapeutic Options for Treating Mood and Anxiety Disorders.
Lowe H; Toyang N; Steele B; Grant J; Ali A; Gordon L; Ngwa W
Molecules; 2022 Apr; 27(8):. PubMed ID: 35458717
[TBL] [Abstract][Full Text] [Related]
8. Psychedelics and mental health: a population study.
Krebs TS; Johansen PØ
PLoS One; 2013; 8(8):e63972. PubMed ID: 23976938
[TBL] [Abstract][Full Text] [Related]
9. United States National Institutes of Health grant funding for psychedelic-assisted therapy clinical trials from 2006-2020.
Barnett BS; Parker SE; Weleff J
Int J Drug Policy; 2022 Jan; 99():103473. PubMed ID: 34624734
[TBL] [Abstract][Full Text] [Related]
10. Psychedelics and Psychedelic-Assisted Psychotherapy.
Reiff CM; Richman EE; Nemeroff CB; Carpenter LL; Widge AS; Rodriguez CI; Kalin NH; McDonald WM;
Am J Psychiatry; 2020 May; 177(5):391-410. PubMed ID: 32098487
[TBL] [Abstract][Full Text] [Related]
11. Cessation and reduction in alcohol consumption and misuse after psychedelic use.
Garcia-Romeu A; Davis AK; Erowid F; Erowid E; Griffiths RR; Johnson MW
J Psychopharmacol; 2019 Sep; 33(9):1088-1101. PubMed ID: 31084460
[TBL] [Abstract][Full Text] [Related]
12. Among psychedelic-experienced users, only past use of psilocybin reliably predicts nature relatedness.
Forstmann M; Kettner HS; Sagioglou C; Irvine A; Gandy S; Carhart-Harris RL; Luke D
J Psychopharmacol; 2023 Jan; 37(1):93-106. PubMed ID: 36601974
[TBL] [Abstract][Full Text] [Related]
13. Illicit use of LSD or psilocybin, but not MDMA or nonpsychedelic drugs, is associated with mystical experiences in a dose-dependent manner.
Lyvers M; Meester M
J Psychoactive Drugs; 2012; 44(5):410-7. PubMed ID: 23457892
[TBL] [Abstract][Full Text] [Related]
14. Second thoughts on psychedelic drugs.
Novak SJ
Endeavour; 1998; 22(1):21-3. PubMed ID: 9588116
[TBL] [Abstract][Full Text] [Related]
15. Knowledge, Perceptions, and Use of Psychedelics among Individuals with Fibromyalgia.
Glynos NG; Pierce J; Davis AK; McAfee J; Boehnke KF
J Psychoactive Drugs; 2023; 55(1):73-84. PubMed ID: 35001856
[TBL] [Abstract][Full Text] [Related]
16. Prevalence and epidemiological associates of novel psychedelic use in the United States adult population.
Sexton JD; Crawford MS; Sweat NW; Varley A; Green EE; Hendricks PS
J Psychopharmacol; 2019 Sep; 33(9):1058-1067. PubMed ID: 30816808
[TBL] [Abstract][Full Text] [Related]
17. Psychedelic perceptions: mental health service user attitudes to psilocybin therapy.
Corrigan K; Haran M; McCandliss C; McManus R; Cleary S; Trant R; Kelly Y; Ledden K; Rush G; O'Keane V; Kelly JR
Ir J Med Sci; 2022 Jun; 191(3):1385-1397. PubMed ID: 34131812
[TBL] [Abstract][Full Text] [Related]
18. Psychedelic use and intimate partner violence: The role of emotion regulation.
Thiessen MS; Walsh Z; Bird BM; Lafrance A
J Psychopharmacol; 2018 Jul; 32(7):749-755. PubMed ID: 29807492
[TBL] [Abstract][Full Text] [Related]
19. The risk of chronic psychedelic and MDMA microdosing for valvular heart disease.
Tagen M; Mantuani D; van Heerden L; Holstein A; Klumpers LE; Knowles R
J Psychopharmacol; 2023 Sep; 37(9):876-890. PubMed ID: 37572027
[TBL] [Abstract][Full Text] [Related]
20. Modern Psychedelic Microdosing Research on Mental Health: A Systematic Review.
Lo DF; Zia H; Rajkumar P; Thakur A; O'Donnell H
Prim Care Companion CNS Disord; 2024 Jan; 26(1):. PubMed ID: 38228068
[No Abstract] [Full Text] [Related]
[Next] [New Search]
